Evidence map›Paper›PMID 33514797›Full record

Trial reportScientific reports2021

Role of circulating endothelial cells in assessing the severity of systemic sclerosis and predicting its clinical worsening.

Maria Luisa Di Martino, Alessandra Frau, Francesca Losa, Emma Muggianu, Mario Nicola Mura, Gianluca Rotta, Lorenza Scotti, Francesco Marongiu

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Is anticoagulative therapy in systemic sclerosis to be reconsidered?Journal of scleroderma and related disorders · 2024
    Article
  5. Are circulating endothelial cells the next target for transcriptome-level pathway analysis in ARDS?American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maria Luisa Di MartinoDepartment of Medical Sciences and Public Health and Unit of Internal Medicine, University of Cagliari, SS554-km 4,500, 09042, Monserrato, Cagliari, Italy. m.luisadimartino@gmail.com.
Alessandra FrauDepartment of Medical Sciences and Public Health and Unit of Internal Medicine, University of Cagliari, SS554-km 4,500, 09042, Monserrato, Cagliari, Italy.
Francesca LosaDepartment of Medical Sciences and Public Health and Unit of Internal Medicine, University of Cagliari, SS554-km 4,500, 09042, Monserrato, Cagliari, Italy.
Emma MuggianuDepartment of Medical Sciences and Public Health and Unit of Internal Medicine, University of Cagliari, SS554-km 4,500, 09042, Monserrato, Cagliari, Italy.
Mario Nicola MuraDepartment of Medical Sciences and Public Health and Unit of Internal Medicine, University of Cagliari, SS554-km 4,500, 09042, Monserrato, Cagliari, Italy.
Gianluca RottaBecton Dickinson Biosciences Italy, Milan, Italy.
Lorenza ScottiDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Francesco MarongiuDepartment of Medical Sciences and Public Health and Unit of Internal Medicine, University of Cagliari, SS554-km 4,500, 09042, Monserrato, Cagliari, Italy.
University of Cagliari · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial damage and fibro-proliferative vasculopathy of small vessels are pathological hallmarks of systemic sclerosis (SSc). The consequence is the detachment of resident elements that become circulating endothelial cells (CECs). The aim of our study was to evaluate the potential of CECs as biomarker in SSc. We enrolled 50 patients with limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) subset of SSc, who underwent clinical evaluation to establish the organ involvement. CECs were measured by flow-cytometry utilizing a polychromatic panel. An evident difference was observed in CEC counts comparing controls to SSc patients (median 10.5 vs. 152 cells/ml, p < 0.0001) and for the first time, between the two subsets of disease (median lcSSc 132 vs. dcSSc 716 CEC/ml, p < 0.0001). A significant correlation was established between CECs and some SSc clinical parameters, such as digital ulcers, skin and pulmonary involvement, presence of Scl-70 antibodies, nailfold videocapillaroscopy patterns and EUSTAR activity index. After 12 months, CECs correlated with clinical worsening of patients, showing that a number higher than 414 CEC/ml is a strong negative prognostic factor (RR 5.70). Our results indicate that CECs are a direct indicator of systemic vascular damage. Therefore, they can be used as a reliable marker of disease severity.

Indexed as

Microscopic AngioscopyAdultAgedEndothelial CellsFemaleHumansMaleMiddle AgedScleroderma, SystemicSeverity of Illness Index

Identifiers

PMID33514797
PMCPMC7846576
OpenAlexW3123192690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.